8 results about "Acute pneumonia" patented technology

Provided are a universal cell system, a construction method therefor, and use thereof. Universal mesenchymal stem cells are constructed by means of the combination of electroporation and CRISPRoff gene editing, and the cells can survive stably in a pulmonary inflammatory pathological environment to provide sustained treatment, significantly improve multiple indicators of acute pneumonia, solve immune rejection, and provide new cell therapies and ideas for acute pneumonia. CRISPRoff is introduced into universal CTL cells by means of electroporation technology, targeting a specific region and inhibiting the expression of HLA-I in T cells; thus, T cells with low immunogenicity are constructed, and the cells can avoid allogeneic immune rejection. The universal cell system combines the advantages of both transient transfection and CRISPRoff gene editing, has great significance in the field of cell therapy, provides a more comprehensive and effective solution for the treatment of various diseases, and has a wide application prospect.

The invention discloses an establishment and application method of an acute pneumonia animal model for an acinetobacter baumannii vaccine immune effect test, and the method comprises the following steps: S1, screening experimental animals, and feeding; s2, experiment grouping and identification; s3, constructing an animal model; and S4, performing data statistical analysis. According to the animal model, common clinical infection pathways, infection parts, pathogenesis, pathological changes and clinical manifestations of the acinetobacter baumannii can be simulated to the maximum extent, and the pertinence and accuracy of candidate vaccine curative effect judgment and prediction are improved.

The application relates to the technical field of stem cells, in particular to a cell subpopulation and application thereof. ‑ The application discloses a mesenchymal stem cell with stronger anti-inflammatory effect and weaker pro-inflammatory potential, which can avoid treatment resistance and promote improvement of treatment effect when applied to treatment of acute pneumonia mice, and has good clinical application value.

The invention discloses a screening and action mechanism research method for anti-pneumonia active ingredients of Xiaobai powder, and relates to the technical field of biological medicines, and the technical key points are as follows: three acute pneumonia animal models simulating the inducement characteristics of'infantile pneumonia 'are constructed, so that XBS anti-pneumonia efficacy evaluation is more representative; meanwhile, preliminary screening is carried out by applying a spectrum-activity correlation modeling technology, then pharmacodynamic active ingredients of XBS for treating pneumonia are screened by virtue of an anti-inflammatory drug luciferase reporter gene system of an NF-kappa B signal channel, so that the subsequent analysis work is more concentrated, and a Poly-PK / PM-PD comprehensive strategy is adopted, so that the accuracy of screening is improved. The pharmacodynamic action mechanism of XBS for treating pneumonia is explained from dynamic change correlation of four groups of quantitative data, a new thought is provided for treating infantile lung heat cough and asthma, and meanwhile, the characteristics of progressive and multi-path effects of a compound traditional Chinese medicine are also shown.

This invention relates to the field of molecular biology, and more specifically, to a novel application of *Tea glomerata* exovesicles, namely, their application in the preparation of anti-inflammatory drugs, specifically in drugs for treating acute pneumonia. The method for preparing *Tea glomerata* exovesicles includes the following steps: Fresh *Tea glomerata* slices are juiced, and the juice is collected. The juice is centrifuged sequentially, and the supernatant from the third centrifugation is collected and centrifuged at 120,000-140,000g for 50-60 minutes to obtain a crude extract. The crude extract is added to a gradient concentration sucrose solution, centrifuged, and a solution containing 30%-45% bands is collected. This solution is then centrifuged at 150,000-160,000g for 50-60 minutes to obtain the *Tea glomerata* exovesicles. The method of this invention can yield *Tea glomerata* exovesicles that meet standards and have stable quality.

The invention discloses an alveolar macrophage inhibitory natural product monomer and application thereof, and relates to the technical field of biological medicines. Seven natural product monomers including polyphyllin B, gentisic acid, catalpol, abscisic acid, aescin, ginsenoside and guaiacol are obtained through screening, and the menin / SETD2 interaction can be specifically inhibited. Experiments show that the monomers can inhibit expression of various inflammatory factors such as IL-1alpha, IL-1beta, IL-6 and the like induced by LPS in a dose-dependent manner; animal experiments prove that the monomers can obviously inhibit release of inflammatory factors induced by pathogens such as LPS and streptococcus pneumoniae, and can effectively relieve acute pneumonia and lung injury of mice. The provided natural product monomer is clear in target spot, specific in effect and broad in anti-inflammatory effect spectrum, and has important application prospects in treatment of cell / inflammatory factor storm related diseases caused by abnormal activation of alveolar macrophages.

The invention relates to the technical field of biological medicines, in particular to application of 5, 7, 4 '-trihydroxy-6, 3', 5 '-trimethoxyflavone, 5, 4'-dihydroxy-6, 7-dimethoxyflavone and 5, 4 '-dihydroxy-3', 6, 7-trimethoxyflavone which are separated from artemisia wissmanniana to preparation of medicines for preventing and treating lipopolysaccharide-induced acute pneumonia or acute lung injury of mice, and particularly relates to application of 5, 7, 4 '-trihydroxy-6, 3', 5 '-trimethoxyflavone, 5, 4'-dihydroxy-6, 7-dimethoxyflavone and 5, 4 '-dihydroxy-3', 6, 7-trimethoxyflavone to preparation of medicines for preventing and treating lipopolysaccharide-induced acute pneumonia or acute lung injury of mice. Experiments prove that the monomer and the composition play a remarkable comprehensive prevention and treatment role by down-regulating expression of a proinflammatory factor, promoting generation of an anti-inflammatory factor IL-10, reducing the wet-to-dry weight ratio of the lung and reducing the activity of total protein and neutrophil elastase in alveolar lavage fluid. The invention aims to provide a technical scheme for multi-target intervention of acute pneumonia through natural active molecules.

The application discloses THK01 and derivatives thereof, a preparation method and application of the THK01 and the derivatives in preparation of anti-inflammatory drugs, and relates to the following steps: a series of chemical reactions, including Wittig reaction, Diels-Alder reaction, Cadogan reaction, Fischer indole synthesis reaction, demethylation reaction, reduction reaction and click chemistry reaction, are carried out on ortho-nitrobenzaldehyde containing specific substituents, so that THK01 structural modification derivatives with different substituents are obtained. The THK01 structural modification derivatives are synthesized in various routes, and the reaction success rate is high. In vitro and in vivo experiments show that the compounds can significantly inhibit the production of NO and inflammatory reactions at a low concentration, and can effectively treat inflammatory bowel disease and H1N1 virus-induced acute pneumonia in an animal model. The findings provide valuable candidate compounds and new treatment strategies for developing new, safe and efficient anti-inflammatory drugs.